Methods
The trial design was:
- multicentre
- randomised
- double-blind
- double-dummy
449 patients were enrolled into the trial within 30 hours from the onset of symptoms. Haemorrhagic stroke was excluded by a CT scan.
- the aspirin group received 160 mg daily
- LMWH group received 100 IU/kg twice daily
Patients were assessed at day 14 for:
- recurrent stroke
- secondary endpoints:
- cerebral haemorrhage
- progression of symptoms within the first 48 hrs
- death
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.